SecBot SecBot

RIGL

RIGEL PHARMACEUTICALS INC
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001034842 Biotech & Drug Discovery
$43.73 −0.73 (−1.64%)
Nov 16 4:00 PM ET · prev $44.46
Market cap
$860.3M
Small cap
Consensus
Buy
73% Buy or better · 11 analysts
Median target
$55.00
+26% · range $47.00–86.00
1 year
+2.9%
from $42.51 · Nov 17
30 days
−6.4%
from $46.72
52-week range
$25.44–51.45
−15% from high · low Mar 18
Avg volume 20D
253.6K
Nov 6 spike 759.1K
Short interest
2.54M
≈13.5% of shares · −7.2%
Days to cover
12.9
at average volume
Insider net
−$305.9K
0 buyers · 2 sellers · 12 mo
New fund stakes
1
Q3 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 1 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $305.9K.

  • InstitutionsMIXED

    Q3 2026: 22 added (1 new), 18 trimmed or exited. Largest new: Assenagon Asset Management S.A $25.8M.

  • AnalystsBULLISH

    8 of 11 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −7.2% to 2.54M shares. 12.9 days to cover, ≈13.5% of shares.

  • TrendDOWNTREND

    8% below its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
0
exits
$25.8M
in new stakes
FundMoveSharesValue
MORGAN STANLEYDOUBLED1,256,819$60.5M
AMERICAN CENTURY COMPANIES INCADD1,043,966$50.3M
Assenagon Asset Management S.A.NEW535,685$25.8M
UBS Group AGADD175,627$8.5M
DIMENSIONAL FUND ADVISORS LPTRIM100,717$4.8M
CREDIT AGRICOLE S ADOUBLED78,164$3.8M
RENAISSANCE TECHNOLOGIES LLCTRIM73,119$3.5M
Nuveen, LLCTRIM50,613$2.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 73% rate it Buy or better
Strong Buy4Buy4Hold3Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +26%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026Citigroup
MAINTAIN
MAINTAINBuy
Nov 6, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINNeutral
Oct 19, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 17, 2026Piper Sandler
MAINTAIN
MAINTAINNeutral
Aug 14, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jun 18, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINNeutral

Insider ledger

Form 4
$0
bought · 0 insiders
$305.9K
sold · 2 insiders
DateInsiderTypeValue
Sep 2, 2026
Schorno Dean L
EVP & Chief Financial Officer
Sep 2, 2026
EXERCISE$8.8K
Sep 2, 2026
Schorno Dean L
EVP & Chief Financial Officer
Sep 2, 2026
EXERCISE$48.4K
Sep 2, 2026
Schorno Dean L
EVP & Chief Financial Officer
Sep 2, 2026
EXERCISE$11.6K
Sep 2, 2026
Schorno Dean L
EVP & Chief Financial Officer
Sep 2, 2026
EXERCISE$31.1K
Sep 1, 2026
Furey Raymond J.
EVP, GC, CCO & Corp Sec
Sep 1, 2026
TAX W/H$41.7K
Sep 1, 2026
Santos David A
EVP, Chief Commercial Officer
Sep 1, 2026
TAX W/H$41.5K
Sep 1, 2026
RODRIGUEZ RAUL R
CEO, President
Sep 1, 2026
TAX W/H$115.1K
Sep 1, 2026
Schorno Dean L
EVP & Chief Financial Officer
Sep 1, 2026
TAX W/H$44.1K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
2,535,665
shares short
-7.2%
vs prior settlement
12.9
days to cover
≈13.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 SEC
Morgan Stanley filed a Schedule 13G disclosing a 6.5% passive stake in Rigel Pharmaceuticals as of September 30, 2026…
SC 13G · Impact 3/10
Nov 10, 2026 SEC
State Street Corporation filed a Schedule 13G disclosing a 4.7% passive stake in Rigel Pharmaceuticals as of September…
SC 13G · Impact 3/10
Nov 10, 2026 Other
Rigel to Present at the Jefferies Global Healthcare Conference in London
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL
Sep 30, 2026 Inst.
MORGAN STANLEY · DOUBLED
1,256,819 shares ($60.5M)
Sep 30, 2026 Inst.
AMERICAN CENTURY COMPANIES INC · ADD
1,043,966 shares ($50.3M)
Sep 2, 2026 Insider
Schorno Dean L acquired via exercise 694 shares
EVP & Chief Financial Officer @ $12.70 ($8.8K)
Sep 2, 2026 Insider
Schorno Dean L acquired via exercise 2,000 shares
EVP & Chief Financial Officer @ $24.20 ($48.4K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 10, 2026
Press release
Rigel to Present at the Jefferies Global Healthcare Conference in London
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company…
Nov 2, 2026
Earnings date
RIGL Q3 2026 Earnings Scheduled · 2026-11-02
Oct 29, 2026
Earnings
Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third…
Oct 2, 2026
Press release
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted…
Sep 2, 2026
Press release
Rigel to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company…

SecBot reports

12 filings · 1 bullish · 3 bearish · 1 mixed · 7 neutral
All RIGL filing & press-release reports (12)